Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Zolpidem: distinct from triazolam?

Lobo BL, Greene WL.

Ann Pharmacother. 1997 May;31(5):625-32. Review.

PMID:
9161660
2.

Comparative clinical profiles of triazolam versus other shorter-acting hypnotics.

Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW.

J Clin Psychiatry. 1992 Dec;53 Suppl:19-31; discussion 32-3. Review.

PMID:
1336776
3.
4.

Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans.

Morgan PT, Kehne JH, Sprenger KJ, Malison RT.

J Sleep Res. 2010 Mar;19(1 Pt 2):157-64. doi: 10.1111/j.1365-2869.2009.00757.x. Epub 2009 Aug 13.

5.
6.

Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients.

Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL.

Pharmacopsychiatry. 1994 Jul;27(4):166-75.

PMID:
7972349
7.

Comment: zolpidem: distinct from triazolam?

Holt RJ, Allard S.

Ann Pharmacother. 1997 Nov;31(11):1408-13. No abstract available.

PMID:
9391705
8.

Zolpidem for insomnia.

Greenblatt DJ, Roth T.

Expert Opin Pharmacother. 2012 Apr;13(6):879-93. doi: 10.1517/14656566.2012.667074. Epub 2012 Mar 19. Review.

PMID:
22424586
9.

Zolpidem: a review of its use in the management of insomnia.

Swainston Harrison T, Keating GM.

CNS Drugs. 2005;19(1):65-89. Review.

PMID:
15651908
10.
11.

Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia.

Hoehns JD, Perry PJ.

Clin Pharm. 1993 Nov;12(11):814-28. Review. Erratum in: Clin Pharm 1993 Dec;12(12):881.

PMID:
8275648
12.

Minimal rebound insomnia after treatment with 10-mg zolpidem.

Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW.

Clin Neuropharmacol. 1997 Apr;20(2):116-25.

PMID:
9099463
13.

Hypnotics in insomnia: the experience of zolpidem.

MacFarlane J, Morin CM, Montplaisir J.

Clin Ther. 2014 Nov 1;36(11):1676-701. doi: 10.1016/j.clinthera.2014.09.017. Epub 2014 Nov 19. Review.

PMID:
25455931
14.

Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil.

Wesensten NJ, Balkin TJ, Davis HQ, Belenky GL.

Psychopharmacology (Berl). 1995 Sep;121(2):242-9.

PMID:
8545530
15.

A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.

Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F.

Eur Arch Psychiatry Clin Neurosci. 2001 Jun;251(3):117-23.

PMID:
11697572
16.

Extended-release zolpidem: efficacy and tolerability profile.

Owen RT.

Drugs Today (Barc). 2006 Nov;42(11):721-7. Review.

PMID:
17171191
17.

Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.

Rush CR, Baker RW, Wright K.

Psychopharmacology (Berl). 1999 Jun;144(3):220-33.

PMID:
10435388
18.

Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies.

Rosenberg RP.

Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56. Review.

PMID:
16517453
19.

Sublingual zolpidem (Edluar™; Sublinox™).

Yang LP, Deeks ED.

CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y. Review.

PMID:
23034583
20.

Insomnia.

Lobo BL, Greene WL.

N Engl J Med. 1997 Jun 26;336(26):1919. No abstract available.

Supplemental Content

Support Center